XML 18 R7.htm IDEA: XBRL DOCUMENT v3.26.3
Note 1 - Organization and Nature of Operations
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

Note 1. Organization and Nature of Operations

 

The Company

 

Flyte Aviation, Inc. (formerly known as Catheter Precision, Inc.) (the "Company”) was incorporated in California on September 4, 2002, and reincorporated in Delaware in July 2018. On January 9, 2023, the Company entered into the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement") with Catheter Precision, Inc. (“Old Catheter”), a privately held Delaware corporation. Under the terms of the Merger Agreement, Old Catheter became a wholly owned subsidiary of the Company, together referred to as the Company, in a stock-for-stock merger transaction (the "Merger"). The Company's operating activities primarily related to Old Catheter's historical business, which included the design, manufacture and sale of new and innovative medical technologies in the field of cardiac electrophysiology (“EP”). 

 

On February 17, 2025, the Company formed Cardionomix, Inc. ("Cardionomix"), an 82%-owned subsidiary. On May 5, 2025, Cardionomix acquired certain assets primarily related to the Cardiac Pulmonary Nerve Stimulation ("CPNS") System, a technology for the late-stage treatment of acute decompensated heart failure.

 

On February 6, 2026, the Company entered into Securities Agreement with SEG Jets LLC ("SEG Jets"), whereby the Company agreed to acquire 19.98% of the issued and outstanding shares of common stock of Fly Flyte, Inc. ("FLYTE") held by SEG Jets. On March 9, 2026, the Company entered into Stock Agreement with Creatd, Inc. ("Creatd") and acquired the remaining 80.02% of the issued and outstanding shares of common stock of FLYTE and all of FLYTE’s wholly owned consolidated subsidiaries, which included 100% equity ownership interest in Ponderosa Air, LLC. As a result of these transactions (collectively the "Acquisition"), the Company owns 100% of the issued and outstanding common stock of FLYTE and its wholly owned consolidated subsidiaries. FLYTE and all of its wholly owned consolidated subsidiaries operate as a single business.

 

Effective October 5, 2026, the Company changed its legal name from Catheter Precision, Inc. to Flyte Aviation, Inc. In connection with the name change, the ticker symbol for the Company’s common stock listed on the NYSE American changed from “VTAK” to “VJET” effective October 5, 2026.

 

After the Acquisition, the Company's operations are organized and managed under two reportable segments: (i) cardiac electrophysiology and (ii) private aviation.

 

Cardiac Electrophysiology Segment

 

Historically, the Company's cardiac electrophysiology operations included the VIVO System, a non-invasive imaging system that provides three-dimensional cardiac mapping to assist in identifying the origin of certain ventricular arrhythmias, and LockeT, a suture retention device used to facilitate vascular access site closure following certain medical procedures. The Company began commercial sales of VIVO in the United States in 2021 and LockeT in 2024. In September 2026, the Company began negotiations for the sale of its VIVO and LockeT businesses and accordingly classified these businesses as discontinued operations and the related Disposal Group (as defined below) as held for sale. Accordingly, their results of operations are excluded from continuing operations for all periods presented. The remaining cardiac electrophysiology segment includes certain legacy medical technology assets and related activities that are not included in the Disposal Group. See Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

Private Aviation Segment

 

Through its wholly owned subsidiary, the Company operates a private aviation company providing regional private jet charter services through its fleet of leased Cirrus Vision jets and charter brokerage services through third-party operators. Charter customers are sourced through a network of brokers who make a market between customers and private aviation companies, and also through its recently launched Direct to Consumer app and website. The subsidiary’s business strategy includes providing low-cost private aviation compared to traditional charter services as an alternative to driving on regional routes, generally within 400 nautical miles of its base in Farmingdale, New York. The Company’s recently launched app enables customers to quickly and easily book and pay for flights and has begun to create and increase brand awareness among the Company’s target market of customers who choose to reduce the time required to travel to and from destinations with the speed of flight. The Company has also recently launched the ability for customers to bid to fly on empty-leg segments intended to turn those segments into cost-neutral or profitable flights. The Company had begun the regulatory approval process to operate flights to and from Canada, Mexico and the Caribbean.  During the 2026 third quarter, the Company received the required approvals to operate flights in Mexico and the Caribbean.  Additionally, on October 29, 2026 the Company announced that it had received the required approvals to operate flights within Canada.

 

Reverse Stock Split

 

On April 15, 2026, at a Special Meeting of Stockholders of the Company, the stockholders approved an Amendment to the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split within specified parameters. On September 24, 2026, the Board approved the Amendment and set the ratio of the reverse stock split at 1-for-10. The Amendment was effective October 5, 2026, effecting a reverse stock split in which each ten (10) shares of the Company’s common stock, par value $0.0001 per share, issued and outstanding immediately prior to the effective time, automatically combined into one (1) validly issued, fully paid and non-assessable share of the Company’s common stock, par value $0.0001 per share.

 

No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share were entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). All references to share and per share amounts for all periods presented in the unaudited condensed consolidated financial statements have been retrospectively restated to reflect the reverse stock split. All rights to receive shares of common stock under outstanding securities, including but not limited to, warrants, options and convertible securities, were adjusted to give effect to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise and conversion prices and the number of shares of common stock that may be purchased or issued upon exercise or conversion of outstanding warrants, stock options and convertible securities, and the number of shares of common stock reserved for future issuance under the Company’s 2023 Equity Incentive Plan.

 

Going Concern

 

The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from uncertainty related to its ability to continue as a going concern.

 

The Company has incurred recurring net losses from operations and negative cash flows from operating activities since inception. For the nine months ended September 30, 2026, the Company incurred $20.1 million in net losses and used $10.2 million in cash for operating activities. As of September 30, 2026, the Company had an accumulated deficit of $329.6 million, working capital deficit of $3.2 million, and cash and cash equivalents of $2.4 million.

 

Management expects operating losses and negative cash flows to continue for the foreseeable future. The Company needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its private aviation operations, retained medical technology activities, and other contractual and operating obligations. 

 

During the nine months ended September 30, 2026, the Company raised aggregate gross proceeds of approximately $18.7 million from the sale of common stock and Series C Convertible Preferred Stock and the exercise of warrants (see Note 13, Equity Offerings, and Note 14, Preferred Stock). In October 2026, certain existing investors agreed to purchase an additional $2.05 million of Series C-4 Convertible Preferred Stock, and on November 1, 2026, the Company entered into a non-binding letter of intent for the sale of the Disposal Group (as defined in Note 4, Discontinued Operations and Assets Held for Sale) (see Note 20, Subsequent Events). There can be no assurance that the sale of the Disposal Group will be completed or as to the amount or timing of any proceeds.

 

Based on the Company's liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of the unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the Company continuing to operate in the normal course of business and do not reflect any adjustments to the assets and liabilities related to the substantial doubt of its ability to continue as a going concern.

 

Management plans to raise additional capital through public or private equity or debt financing, or other innovative and specialty finance strategies, in order to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the unaudited condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders.